Highlights from the Gastrointestinal and Genitourinary Cancer Conferences
Here are some of the top stories from the recent Gastrointestinal Cancers Symposium as well as the Genitourinary Cancers Symposium.
Source: curetoday.com
📰 Michiels Van News
Michiels Van News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Michiels Van. Real-time updates on events, politics, business and more.
Survival Benefits with Keytruda and Padcev in Advanced Urothelial Cancer
Patients with previously untreated locally advanced or metastatic urothelial carcinoma experienced favorable progression-free survival, overall survival and objective response rates when treated with Padcev and Keytruda versus chemotherapy.
United States Padcev Keytruda Michiels Van Michiel Van Der Heijden Research Group Netherlands Cancer Institute Drug Administration
Source: curetoday.com
Enfortumab Vedotin Plus Pembrolizumab Maintains Survival Advantage Across Advanced Urothelial Cancer Subgroups
Enfortumab vedotin plus pembrolizumab showed consistent overall survival and progression-free survival benefit in all patients enrolled in EV-302.
Perez Valderrama Michiels Van Bristol Myers Squibb Astellas Pharma Gilead Sciences Cancers Symposium
Source: onclive.com
Frontline Nivolumab Plus Chemotherapy Boosts OS and PFS in Metastatic Urothelial Carcinoma
Concurrent frontline nivolumab and gemcitabine-cisplatin followed by nivolumab maintenance therapy elicited OS and PFS benefits vs gemcitabine-cisplatin alone in patients with previously untreated, metastatic or unresectable urothelial carcinoma.
Noord Holland Michiels Van Netherlands Cancer Institute Concurrent Frontline Nivolumab And Gemcitabine Cisplatin Urothelial Carcinoma Checkmate 901 Study
Source: onclive.com
Opdivo Plus Chemo Betters Survival in Urothelial Carcinoma
Adding Opdivo to a standard-of-care chemotherapy regimen in patients with unresectable or metastatic urothelial carcinoma improved progression-free and overall survival.
Source: curetoday.com